Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $24.48 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 264,993 shares of the biopharmaceutical company’s stock after selling 6,030 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Gilead Sciences were worth $24,477,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its holdings in shares of Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. FMR LLC lifted its position in Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC increased its holdings in Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after purchasing an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Gilead Sciences by 3.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock worth $739,217,000 after purchasing an additional 249,804 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of analyst reports. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Thursday, February 13th. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Morgan Stanley increased their price target on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, March 11th. Finally, The Goldman Sachs Group boosted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $104.52.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,503,250. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Down 1.5 %

NASDAQ:GILD opened at $105.87 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The stock’s fifty day moving average price is $103.33 and its two-hundred day moving average price is $93.56. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market cap of $131.84 billion, a P/E ratio of 286.14, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.98%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.